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ORIGINAL ARTICLE
DCE-MRI for Early Prediction of Response in 
Hepatocellular Carcinoma after TACE and Sorafenib 
Therapy: A Pilot Study
Kazuhiro Saito*, Joseph Ledsam†, Katsutoshi Sugimoto*, Steven Sourbron†, Yoichi Araki* 
and Koichi Tokuuye*
Objective: Dynamic contrast-enhanced MRI (DCE-MRI) can measure the changes in tumor blood flow, 
vascular permeability and interstitial and intravascular volume. The objective was to evaluate the efficacy 
of DCE-MRI in prediction of Barcelona Clinic Liver Cancer (BCLC) staging B or C hepatocellular carcinoma 
(HCC) response after treatment with transcatheter arterial chemoembolization (TACE) followed by 
sorafenib therapy.
Methods: Sorafenib was administered four days after TACE of BCLC staging B or C HCC in 11 patients 
(21 lesions). DCE-MRI was performed with Gd-EOB-DTPA contrast before TACE and three and 10 days 
after TACE. DCE-MRI acquisitions were taken pre-contrast, hepatic arterial-dominant phase and 60, 120, 
180, 240, 330, 420, 510 and 600 seconds post-contrast. Distribution volume of contrast agent (DV) and 
transfer constant Ktrans were calculated. Patients were grouped by mRECIST after one month or more 
post-TACE into responders (complete response, partial response) and non-responders (stable disease, 
progressive disease).
Results: DV was reduced in responders at three and 10 days post-TACE (p = 0.008 and p = 0.008 
respectively). DV fell in non-responders at three days (p = 0.025) but was not significantly changed from 
pre-TACE values after sorafenib. Sensitivity and specificity for DV 10 days post-TACE were 88% and 77% 
respectively. 
Conclusion: DV may be a useful biomarker for early prediction of therapeutic outcome in intermediate 
HCC.
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Introduction
Sorafenib is a multi-kinase inhibitor drug that provides 
clinical benefit advanced hepatocellular carcinoma 
(HCC). It lengthens the duration of stable disease 
impacting both real and quality-adjusted life years [1]. 
However, it is an expensive therapy and the prevalence 
of adverse effects is relatively high. Early prediction of 
response could help avoid unnecessary patient suffering 
and offer additional economic benefits.
The combination of sorafenib with transcatheter 
arterial chemoembolization (TACE) has revealed good 
therapeutic results [2–5]. TACE is the standard therapy for 
intermediate HCC cases where surgery is not possible or 
is contraindicated. Because TACE enhances the production 
of angiogenic factors such as vascular endothelial growth 
factor (VEGF), it increases the possibility of metastasis 
and recurrence [6]; administering a course of sorafenib 
alongside TACE can reduce this risk. This presents a 
problem for follow up: TACE response is usually evaluated 
on dynamic CT or MRI studies and local recurrence by 
the presence of enhancement on arterial phase. Standard 
dynamic studies are unable to evaluate the effect of 
molecular target therapies such as sorafenib. There is a 
clinical need for both evaluation and early prediction of 
HCC response after the combination of sorafenib and 
TACE.
 Functional imaging methods can help solve these 
problems. Dynamic contrast-enhanced MRI (DCE-MRI) 
appears to be well correlated with immunohistochemical 
findings of antiangiogenic, antiproliferative and 
proapoptotic effects [7]. DCE-MRI can measure the 
changes in tumor blood flow, vascular permeability and 
interstitial and intravascular volume that result from 
these effects. 
We evaluate the efficacy of tracer kinetic modelling 
of DCE-MRI in the early prediction of intermediate HCC 
response after treatment with TACE followed by sorafenib 
therapy.
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Materials and Methods
This prospective study was institutional review board 
approved (Tokyo Medical University, #1149) and informed 
consent was obtained. 
Subjects
Eleven patients (8 male, 3 female: mean age 65 years) with 
21 hepatocellular carcinoma lesions (mean ± standard 
deviation largest dimension: 22.6 ± 17.9 mm) were 
included in this study. Tumors were diagnosed 
pathologically and/or based on the criteria of the 
American Association for the Study of Liver Disease 
using abdominal dynamic CT, dynamic MRI using 
gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic 
acid (Gd-EOB-DTPA) or contrast-enhanced US [8]. A 
maximum of two lesions were included per patient to 
avoid sampling bias. The two largest HCC lesions were 
chosen if more than two lesions were present. The study 
inclusion criteria were an initiation on sorafenib therapy, 
Barcelona Clinic Liver Cancer (BCLC) staging B or C, 
no contraindications to MRI, and an interval between 
DCE-MRI before TACE and TACE of no greater than two 
weeks. Patients were excluded if they were eligible for 
surgical or locoregional therapy, or if life expectancy was 
less than 12 weeks.
Therapy
All patients underwent TACE, followed after four days by 
sorafenib therapy. The initial dose of sorafenib was 400mg 
daily and this was increased by oncology physicians if no 
adverse effects were experienced. TACE were performed 
using an epirubicin hydrochloride (Nippon kayaku, Tokyo, 
Japan)-lipiodol (an ethyl ester of iodinated poppyseed 
oil fatty acids) emulsion or miriplatin hydrate (Miripla®; 
Dainippon Sumitomo Pharma, Co. Ltd., Osaka, Japan)-
lipiodol suspension. Epirubicin-lipiodol emulsion 
consisted of 18–70 mg epirubicin and 4–10 ml of lipiodol 
in 10 cases. Miriplatin hydrate-lipiodol suspension was 
140 mg miriplatin and 10 ml lipiodol in a remaining case. 
The dose was determined by the tumor size, number of 
lesions and liver function [9]. Gelatin sponge particles 
(Gelpart®; Nippon Kayaku, Tokyo, Japan) followed the 
injection of the emulsion until stoppage of the feeding 
arterial flow. Embolic material was injected via segmental 
artery, right or left hepatic arteries.
DCE-MRI
MR imaging was performed with a 1.5 Tesla (T) scanner 
32-channel coil system (Avanto, Siemen Medical Systems, 
Erlangen, Germany) with a peak slew rate of 200 T/m/s. 
DCE-MRI was performed with T1-weighted 3D gradient 
echo sequence with fat saturation and volumetric 
interpolated breath-hold examination (VIBE; Siemens). The 
sequence parameters were as follows: TR/TE = 2.64/0.98 
ms, slice thickness 3 mm, field of view = 400 mm × 68.8%, 
effective matrix size = 320 × 70%, signal averages = 1, 
acquisition time = 6 seconds, k-space trajectory, linear filling. 
DCE-MRI was performed pre-TACE and three and 10 days 
after TACE. Gadolinium-ethoxybenzyl-diethylenetriamine 
pentaacetic acid (Gd-EOB-DTPA; Primovist, Bayer) of 0.025 
mmol/kg was injected at 2 ml/s via the antecubital vein. 
DCE-MRI acquisitions of five images over 30 seconds in 
each phase were taken pre-contrast, at the hepatic arterial-
dominant phase and at 60, 120, 180, 240, 330, 420 510 and 
600 seconds post-contrast Figure 1.
Follow-up
Follow-up imaging was performed with dynamic CT, 
MRI or CT during hepatic arteriography after one 
month or more post-TACE. The perfusion MRI was 
Figure 1: DCE-MRI acquisitions of five images over 30 seconds in each phase were taken pre-contrast, at the hepatic 
arterial-dominant phase and at 60, 120, 180, 240, 330, 420 510 and 600 seconds post-contrast.
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used for evaluating outcome at three and 10 days post-
TACE. Dynamic CT was performed with either a 16- or 
64-detector row CT. Contrast agent (Iohexol 300, Daiichi-
Sankyo, Tokyo, Japan) was injected over 30 s [10]. The 
amount of contrast agent used was 600 mgI/kg [11]. The 
arterial-dominant phase was obtained using a monitor 
scan; following this the portal-dominant phase and 
equilibrium phase were obtained at 60 seconds and 
four minutes after injection of contrast media. Dynamic 
MRI was performed using Gd-EOB-DTPA. Gd-DTPA was 
injected at a rate of 2 mL/s via the antecubital vein, 
followed by 40 mL of physiological saline. The total 
amount of contrast media used was 0.025 mmol/kg. 
Dynamic study included the hepatic arterial-dominant 
phase, portal-dominant phase, and period four minutes 
after injection of the contrast material. We used a 
3D-VIBE with the dynamic study, with the following 
parameters: TR/TE, 4.28/1.78 ms; flip angle, 15°; matrix 
256 × 217; PAT factor, 2; slice thickness, 3 mm; and 
acquisition time, 20s. The monitoring scan technique 
(Care Bolus method) was used to obtain the optimal 
arterial phase. The hepatobiliary phase was obtained 
by 3D-VIBE 20 minutes after injecting the contrast 
material. Angiography-assisted CT was performed with 
an angiography-combined 16-detector row CT system 
(Advantx ACT; GE Medical Systems, Milwaukee, WI). CTHA 
was performed six seconds after the injection of contrast 
material through a catheter in the common hepatic 
artery or proper hepatic artery. A total of 10–30 mL of 
contrast material (Iomeprol 350 mgI/mL; Eisai, Tokyo, 
Japan) was injected at a rate of 0.8–1.5 mL/s. CTHA was 
carried out in three phases. Immediately after finishing 
the first phase, the second phase was obtained, and the 
third phase was obtained two minutes after beginning 
the injection of contrast material. The parameters for CT 
acquisition were as follows: table speed, 13.7 mm/0.5s; 
collimation, 10 mm; and reconstruction, 5 mm.
 Based on this the modified response evaluation 
criterion in solid tumors (mRECIST) was used to group 
lesions into responders (complete response (CR) and 
partial response (PR)) and non-responders (stable disease 
(SD) and progressive disease (PD)) [12]. Each category was 
defined as follows: 
CR = Disappearance of any intratumoral arterial 
enhancement in all target lesions.
PR = At least a 30% decrease in the sum of diameters 
of viable (enhancement in the arterial phase) target 
lesions, taking as reference the baseline sum of the 
diameters of target lesions.
SD = Any cases that do not qualify for either PR or PD.
PD = An increase of at least 20% in the sum 
of the diameters of viable (enhancing) target 
lesions, taking as reference the smallest sum of 
the diameters of viable (enhancing) target lesions 
recorded since treatment started.
Post-processing
Post-processing was performed by one of the authors with 
four years’ experience in quantitative DCE-MRI analysis 
using the software PMI 0.4 [13], blinded to the lesion 
mRECIST category.
Arterial input functions were defined semi-automatically 
over five slices inside the abdominal aorta. For each patient 
a plasma flow map was calculated to aid region of interest 
(ROI) selection [14, 15]. Regions of interest were selected 
for manually for lesions on the same plasma flow map, 
taking the whole lesion volume in each region. Each lesion 
ROI was drawn on all slices where the lesion was visible 
under the guidance of a senior hepatobiliary radiologists 
with more than 10 years’ experience.
Concentrations were calculated as the relative signal 
enhancement S(t)/S0-1 [16], where S(t) is the post-contrast 
signal intensity and S0 the pre-contrast signal intensity. A 
fixed haematocrit of 45% was assumed to convert arterial 
blood concentrations into plasma concentrations. A one-
compartment Tofts model was applied to the regions and 
the perfusion parameters distribution volume of contrast 
agent (DV) and transfer constant Ktrans were calculated 
[17, 18].
Blood levels of angiogenesis factors angiopoetin 
(ang2), vascular endothelial growth factor (VEGF) and 
CKIT were measured in each patient [19] pre-TACE and 
three and 10 days post-TACE.
Statistical analysis
Changes in parameter values after sorafenib was compared 
between the responder and non-responder groups 
according to the mRECIST criteria. Responder lesions were 
those classified as CR or PR; non-responder lesions were 
those classified as SD or PD.
Data was analyzed using the software SPSS and 
Microsoft Excel. Changes in perfusion parameters 
DV and Ktrans at pre-TACE, three days after TACE, and 
10 days after TACE were analyzed using the Friedman 
significance test. Differences in perfusion parameters 
between responder and non-responder groups were 
evaluated using the Manny-Whitney U test. The 
Spearman’s Rank Correlation test was performed for 
all perfusion parameters and angiopoetin2, VEGF 
and the proto-oncogene CKIT. As many patients had 
two lesions, the same angiogenesis factor values were 
assigned to each lesion in a single patient. Analysis of 
Variance calculations were used to evaluate changes in 
angiogenesis factors across time. Sensitivity, specificity, 
negative predictive value (NPV) and positive predictive 
value (PPV) were calculated for DV as a predictive test. 
The cut-off for predicting whether a lesion would 
or would not respond was mean plus two standard 
deviations of all lesions that responded according to 
the mRECIST criteria. P values of less than 0.05 were 
considered significant.
Results
The range of the intervals between DCE-MRI before 
TACE and TACE were one to eight days. The interval was 
2.7 ± 2.0 days (mean ± standard deviation).
Therapeutic outcome on a per lesion basis was shown 
in Table 1. The numbers of the lesions classified as CR, 
PR, SD and PD were 5, 3, 11 and 2, respectively. The eight 
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responder lesions occurred in five patients and the 13 
non-responder lesions occurred in eight patients. Two 
patients had both a responder and non-responder lesion.
DV in the responder group was 28.4 ± 12.4, 14.2 ± 7.0 
and 8.6 ± 4.7 (ml/100 ml; mean ± standard deviation) 
pre-treatment, at three days and 10 days post-TACE, 
respectively. DV in the non-responder group was 
32.3 ± 11.6, 24.5 ± 12.1 and 27.0 ± 9.5 (ml/100 ml, 
mean ± standard deviation) pre-treatment, at three 
days and 10 days post-TACE, respectively. DV was 
significantly reduced in all patients after initial TACE 
(p < 0.001). Changes in DV values are shown in Figure 2. 
In responder lesions (eight in total) DV fell progressively 
at both three days and 10 days post-TACE (p < 0.001). 
DV in non-responders (13 in total) was not significantly 
different from pre-TACE values at 10 days (p = 0.025). Fall 
in DV for responders were significant at all time point 
combinations (pre-treatment versus three days post-
TACE, pre-treatment versus 10 days post-TACE, three 
days and 10 days post-TACE; p = 0.008, 0.008 and 0.047 
respectively). A significant fall was observed for DV in 
non-responders between pre-treatment and three days 
post-TACE (P = 0.01); changes in DV for the non-responder 
group between other time intervals were not significant.
Ktrans in the responder group was 145.2 ± 151.3, 
15.9 ± 15.3 and 8.7 ± 9.5 (ml/100 ml/min, mean ± 
standard deviation) pre-treatment, at three days and 10 
days post-TACE, respectively. Ktrans in the non-responder 
group was 67.5 ± 66.5, 105.4 ± 197.3 and 97.0 ± 166.0 
(ml/100 ml/min, mean ± standard deviation) pre-
treatment, at three days and 10 days post-TACE, 
respectively. Ktrans was significantly reduced in the 
responder group (p = 0.002). Changes in Ktrans are shown 
in Figure 3. The Ktrans of responders was significantly 
reduced between pre-treatment and three days post-
TACE (p = 0.008) and pre-treatment and 10 days post-
TACE (p = 0.016). Responder Ktrans did not significantly 
change between three days and 10 days post-TACE.
Table 1: Patients’ demographic data.
Patient gender age segment Size 
(mm)
Outcome 
at 3 days 
post-TACE
Outcome 
at 10 
days 
post-TACE
Final 
outcome
Interval 
between 
pre-TACE 
MRI and 
TACE (day)
Interval 
between 
TACE and 
follow-up 
imaging 
(day)
Type of 
follow-up 
imaging
1 f 79
8 56 PR PR SD
1 74 CTHA
8 21 SD SD SD
2 m 75
6 14 CR CR CR
8 73 CT
3 9 SD CR CR
3 m 66
4 10 SD SD SD
1 40 CT
3 20 CR CR PR
4 m 73
7 11 CR CR SD
1 114 CT
3 10 CR CR SD
5 f 69
7 7 CR CR SD
1 87 CT
5 8 CR CR SD
6 m 60 8 80 PR PR PD 3 51 MRI
7 f 56
4 15 CR CR CR
1 72 CT
1 16 CR CR CR
8 m 68
7 44 PR PR PR
4 68 CT
3 11 CR CR SD
9 m 71
7 11 CR CR PD
4 58 CT
3 31 CR CR SD
10 m 42
4 18 SD SD SD
3 71 CT
3 17 SD SD SD
11 m 56
6 36 PR PR PR
3 71 CTHA
1 29 CR CR CR
f: female, m: male, CR: complete response, PR: partial response, SD: stable disease, PD: progress disease. TACE: Transcatheter arterial 
chemoembolization. CTHA: CT during hepatic arteriography.
Gray shade indicates the presence of the opposite therapeutic outcome lesion per patient basis.
Saito et al: DCE-MRI for HCC after TACE and Sorafenib Art. 40, pp.  5 of 9 
Figure 2: (a) Responder lesions, (b) non-responder lesions. DV was significantly reduced in all patients after initial 
TACE (p < 0.001). In responder lesions DV fell progressively at both 3 days and 10 days post-TACE (p < 0.001). DV 
in non-responders was not significantly different from pre-TACE values at 10 days (p = 0.025). Boxplot shows as 
follows. Upper, middle and lower line in the box shows upper quartile (75 percentiles), median and lower quartile 
(25 percentiles), respectively. Upper whisker = upper quartile + 1.5 × IQR (interquartile range). Lower whisker = lower 
quartile – 1.5 × IQR (interquartile range). IQR = upper quartile (75 percentiles) – lower quartile (25 percentiles).
Figure 3: (a) Responder lesions, (b) non-responder lesions. Ktrans was significantly reduced in the responder group 
(p = 0.002). Ktrans of responders was significantly reduced between pre-treatment and 3 days post-TACE (p = 0.008) 
and pre-treatment and 10 days post-TACE (p = 0.016). Responder Ktrans did not significantly change between 3 days 
and 10 days post-TACE.
There was a significant difference between responder 
and non-responder groups in DV at three and 10 days 
post-TACE (p = 0.045 and p < 0.001 respectively), and in 
Ktrans at 10 days post-TACE (p = 0.029).
Average angiogenesis factor levels at each time point 
are shown in Table 2. Ang2 decreased from pre-treatment 
to 10 days by an average of 705 pg/ml in responders and 
331 pg/mL in non-responders (p = 0.037). A significant 
correlation (r = 0.621, p = 0.03) between DV and ang2 was 
observed. For both VEGF and c-KIT no significant difference 
was observed between the two groups, and no significant 
correlations were found with perfusion parameters.
The sensitivity, specificity and PPV of MR imaging at 
three and 10 days post-TACE which indicate as responder 
are 88%, 31% and 44%, and 100%, 31% and 47%. The 
sensitivity, specificity, NPV and PPV of DV at pre-TACE and 
three and 10 days post-TACE which indicate as responder 
are shown in Table 3, along with positive and negative 
clinical utility indexes, when DV were 40, 30 and 17 
(ml/100 ml) or lower [20].
Discussion
The perfusion parameter DV fell after TACE therapy 
in both responder and non-responder groups. Similar 
changes have been reported by Taouli et al. [21], and 
may in part be explained by the edematous change of 
tumor cells and lipiodol accumulation in the sinusoids. 
This narrows the inter-cellular space and reduces 
extracellular volume resulting in a fall in overall DV. 
Another important factor is that TACE reduces arterial 
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flow and prevents contrast media reaching the lesion. 
In theory flow changes would affect Ktrans but not DV, 
but as the acquisition time is not sufficiently long to fully 
characterize the intracellular phase this will artifactually 
reduce the recorded DV.
DV may be an effective early predictor of response 
to therapy. DV in the responder group significantly 
decreased between three and 10 days post-TACE. One 
reason for this is the added therapeutic effect of sorafenib. 
Other reports have also shown similar changes in Ve 
(extravascular extracellular volume) after anti-angiogenic 
therapy [22–24]. Although in theory if a lesion undergoes 
necrotic change the cellularity would loosen and DV 
would be expected to increase [22], the anti-angiogenic 
effect of sorafenib decreases arterial blood flow and DV 
falls (artifactually, as explained above) as a result. The 
contrast media was unable to fully perfuse the lesions 
resulting in apparent decreases in DV. This is not the 
case in non-responders in whom no significant change 
in DV was observed at 10 days post-TACE. Reperfusion of 
the lesions due to insufficient TACE therapy may in part 
explain this.
The sensitivity and specificity of DV at 10 days post-TACE 
are shown in Table 4. The cut-off value used was crudely 
defined mean plus two standard deviations, but resulted 
in satisfactory predictive performance and clinical utility 
[20]. Future studies with larger sample sizes are needed to 
define a suitable cut-off value.
Pre-treatment DV does not appear to be a suitable 
parameter for predicting response before therapy is 
commenced. There was no significant difference between 
pre-treatment DV in responder and non-responder 
groups. This is consistent with previously reported data 
using anti-angiogenic drugs for pancreatic cancer [24].
Three pro-angiogenic cytokines were compared with 
the perfusion parameters but only DV and Ang2 showed 
significant correlation. One study by Llovet et al. found 
that VEGF and Ang2 (and c-KIT to a lesser extent) predicted 
HCC patient survival with sorafenib therapy [19]. Miyahara 
et al. evaluated the relationship between the eight pro-
angiogenic cytokines and the outcome of sorafenib 
therapy: high expression of Ang2 was associated with 
poor progression free survival and worse overall survival 
[25]. The correlation between DV and Ang2 supports 
this result. Increased vascularity in individual lesions, as 
expected with higher levels of Ang2, will increase the 
recorded DV. Such an increase may signal progression of 
disease and may be useful an early biomarker.
Ktrans values decreased significantly post-therapy 
in the responder group. Sorafenib reduces capillary 
permeability through anti-angiogenic effects on tumor 
microvasculature; this is reflected by the drop in Ktrans 
(which reflects the capitally permeability-surface area 
product, blood flow and intracellular uptake rate). Kim et 
al. reported that Ktrans served as an effective surrogate 
biomarker for HCC treated with radiation followed by 
sorafenib therapy [26], and similar results were obtained 
in this study.
Previous reports on HCC and other primary cancers 
have found Ktrans to be lower even before treatment 
in those responding to anti-angiogenic treatment 
[24, 27, 28]. Although similar results were obtained 
in this study, there was no significant difference. This 
may have been due to the small number of subjects or 
that patients with stable disease were included in non-
responder group. There were several outlier lesions 
with high Ktrans values (>100 ml/100 ml/min) in the 
pre-treatment responder group. Insufficient temporal 
resolution and poor perfusion of some lesions (perhaps 
due to necrotic components of the lesion) may have led 
to poor model performance in these cases and affected 
the parameter estimates.
We hypothesized that Ktrans would correlate with VEGF 
expression as vascular permeability is regulated by VEGF 
Table 3: Sensitivity, specificity, NPV, PPV and clinical utility indexes for DV at pre-TACE and 3 and 10 days post-TACE.
Parameter Sensitivity Specificity PPV NPV Positive CUI Negative CUI
DV pre-TACE 88% 8% 37% 50% 0.322 0.038
DV 3d post-TACE 100% 23% 44% 100% 0.444 0.231
DV 10d post-TACE 88% 77% 70% 91% 0.615 0.699
CUI: clinical utility index.
Table 2: Average values of angiogenesis factors for responder and non-responder lesions.
Angiogenesis
factor
Lesion
classification
Pre-TACE 3 days 
post-TACE
10 days 
post-TACE
Signifiance of 
responder vs 
nonresponder 
change
Ang2 (pg/ml)
Responder
Non-responder
3663
3078
3913
3967
3208
3636
p = 0.037
VEGF (pg/ml)
Responder
Non-responder
69
86
108
83
242
201
p > 0.05
c-KIT (ng/ml)
Responder
Non-responder
9.8
8.5
7.8
8.3
8.2
8.6
p > 0.05
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[29]. VEGF expression is higher in patients with well-
differentiated HCC (especially during the transition from 
portal supply to arterial supply) than in moderately and 
poorly differentiated HCC [30, 31]. In this study VEGF did 
not correlate with Ktrans, and no significant difference 
was observed between responder and non-responder 
groups. All lesions included were hypervascular and more 
lesions were moderately or poorly differentiated in this 
work, perhaps explaining why VEGF expression was not 
so high.
Limitations
The number of subjects was small. This is the first report 
of DCE-MRI in evaluation of TACE followed by sorafenib 
therapy, and we hope future work in this territory will 
expand our findings to large study populations. The 
follow-up period was short and overall survival was not 
evaluated; this study looked only at effect on individual 
tumor response.
This study has discussed changes in vascularity after 
TACE and sorafenib therapy. The use of the intracellular 
contrast agent Primovist means that the parameter DV 
describes plasma, interstitium and intracellular space. DV 
will thus be affected by multiple factors such as changes 
in vasularity, permeability and HCC hepatocyte function. 
A clearer interpretation of vascularity would require 
an extracellular contrast agent. This is also the case for 
interpretation of Ktrans, which may be weighted by both 
endothelial and intracellular transport rates. However, 
Ktrans cannot be evaluated with extracellular contrast 
media. The hepatocyte-specific contrast agent Primovist is 
now mainly used in evaluating HCC. This contrast agent 
can detect not only hypervascular HCC but also early HCC, 
meaning it is well suited for follow-up of HCC during 
treatment.
The spatial resolution and small size of some tumors 
made region selection difficult. Effectively treated 
lesions also show limited contrast enhancement due to 
poor vascular supply. This has a potential for imperfect 
identification and selection of lesion dimensions that may 
bias the results. The temporal resolution was insufficient 
to fully characterize the contrast agent transport rates. This 
was a particular problem in measuring Ktrans accurately 
and the few values >100 ml/100 ml/min recorded provide 
evidence of this.
In conclusion, DV 10 days post-TACE may be a useful 
biomarker in early prediction of therapeutic outcome 
in advanced HCC. Changes in ang2 suggest this may be 
due to reduced vascular remodeling in non-responding 
lesions.
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